SEC Form 4 · accession 0001209191-16-142261

Oruka Therapeutics, Inc. · ORKA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Pres. & Chief Executive Offic · Director

Period of report

Sep 20, 2016

Accepted (ET)

Sep 21, 2016 · 4:09 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000907654

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	Sep 20, 2016	S	1,972	$2.89	D	42,638	D
Common Stock	holding	—	—		—	19,986	I	By InvestocorTrust as sole Trustee
Common Stock	holding	—	—		—	25,459	I	By NFS Custodian for Michael Bristow's IRA

No Table II lines on this filing.

F1Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan")
F2The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $2.88 to $2.89. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.
F3Includes (i) remaining 4,050 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning on 2/27/17, and (ii) 4,581 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 34,007 previously reported shares of common stock held directly.